Scientists at USC Michelson Center for Convergent Bioscience and Japan’s Nagoya University find and test a promising drug that stops cancer by interfering with the cancer cells’ metabolism and other circadian-related functions
A new drug shows potential to halt cancer cells’ growth by stunting the cells’ biological clock.
The findings from scientists at the USC Michelson Center for Convergent Bioscience and Nagoya University’s Institute of Transformative BioMolecules (ITbM) advance a burgeoning area of research: turning the body’s circadian rhythms against cancer.
Their study, conducted on human kidney cancer cells and on acute myeloid leukemia in mice, was published Jan. 23 in the journal Science Advances.
Scientists know that disrupting sleep and other elements of humans’ circadian rhythm can harm health. The same is true for the circadian clock of cells themselves. If researchers could disturb the circadian clock of cancer cells, they theorize, they could potentially hurt or kill those cells.
The scientists found that a molecule named GO289 targets an enzyme that controls the cell’s circadian rhythm. This drug-protein interaction then disrupts the functions of four other proteins that are important for cell growth and survival.
Human bone cancer cells stopped growing when a drug molecule jammed their circadian rhythm during a study that appears in Science Advances. Photo courtesy of the Kay lab at the USC Michelson Center for Convergent Bioscience.
In effect, GO289 can jam the cogs of the cell’s circadian clock, slowing its cycles. And it can do so with little impact to healthy cells.
“In some cancers, the disease takes over the circadian clock mechanism and uses it for the evil purpose of helping itself grow,” said Steve Kay, director of convergent biosciences at the USC Michelson Center and USC Provost Professor of Neurology, Biomedical Engineering and Biological Sciences. “With GO289, we can interfere with those processes and stop the cancer from growing.”
Kay is among several scientists from USC Dornsife College of Letters, Arts and Sciences, USC Viterbi School of Engineering and Keck School of Medicine of USC who are collaborating across multiple disciplines to find new solutions for treating cancer, neurological disease and cardiovascular disease.
Finding the right candidate
On its initial interactions with human bone cancer cells, GO289 appeared to slow the tumors’ circadian clock as it targeted an enzyme, named CK2.
To see if GO289 consistently hindered other cancers in the same way, the scientists then tested it on human kidney cancer cells and on mice with acute myeloid leukemia. They found that GO289 specifically affected cancer cell metabolism and other circadian-related functions that normally would enable the cancer to grow and spread.
Kay is optimistic about the findings. “This could become an effective new weapon that kills cancer,” he said.
The Latest on: Cancer
via Google News
The Latest on: Cancer
- City of Hope to invest $1 billion in new Irvine cancer hospitalon June 25, 2019 at 12:10 am
City of Hope will invest $1 billion in a new hospital and research center on the site of a former air base in Irvine that will enhance the way cancer care is delivered in the region. The large-scale ... […]
- City of Hope to invest $1 billion for cancer treatment and research near Irvine’s Great Parkon June 25, 2019 at 12:01 am
IRVINE – City of Hope will invest more than $1 billion to develop and support a comprehensive cancer campus next to the Orange County Great Park, about $800 million more and four years sooner than ... […]
- New immune checkpoint explored for head and neck canceron June 24, 2019 at 11:09 pm
A checkpoint may delay travelers but it can help give cancer free rein by suppressing the natural immune response that should destroy it, researchers say. Now they want to learn more about how the ... […]
- HPV vaccine for boys could cut cancer rates, research suggestson June 24, 2019 at 5:30 pm
Vaccinating schoolboys against human papillomavirus (HPV) may cut rates of cancers related to the virus in the long term, new research suggests. HPV is a sexually-transmitted infection and some types ... […]
- Can higher prices fix the shortage of a key bladder cancer drug?on June 24, 2019 at 3:39 pm
The June 19 front-page article “For some critical drugs, low prices lead to scarcity” exposed an important flaw in our supposedly “best” health-care system. We need more articles such as this on the ... […]
- Living Vivaciously With Incurable Canceron June 24, 2019 at 2:39 pm
It took Lise Wise 4 years to attend her first support meeting after her diagnosis of Waldenstrom's macroglobulinemia at the age of 44. "It's an indolent cancer that grows slowly," she said, and she ... […]
- Use of 3D mammograms for breast cancer screening increasingon June 24, 2019 at 11:15 am
More women are getting 3D mammograms, which spot breast anomalies more accurately than traditional mammograms, a new study shows. But there are big variations in use across the United States, the ... […]
- More Evidence That Most Cancer Mutations Are Simply The Result Of Bad Luckon June 24, 2019 at 9:20 am
For decades we’ve been told if we don’t smoke, don’t drink, use sunscreen and eat right, we can hope to have a fighting chance against cancer. And while this is certainly true, and genes, lifestyle ... […]
- 'What can I do to help my friend who's been diagnosed with cancer?'on June 24, 2019 at 8:21 am
Added, go to My Music to see full list. ... […]
- Early Breast Cancer Highlights From ASCO 2019on June 24, 2019 at 8:19 am
Key studies on early breast cancer presented at the 2019 annual meeting of the American Society of Clinical Oncology (ASCO) focused on optimal management in the neoadjuvant and adjuvant settings. In ... […]
via Bing News